Stem Cell Research

Disclaimer: This is a machine generated PDF of selected content from our products. This functionality is provided solely for your convenience and is in no way intended to replace original scanned PDF. Neither Cengage Learning nor its licensors make any representations or warranties with respect to the machine generated PDF. The PDF is automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. CENGAGE LEARNING AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the machine generated PDF is subject to all use restrictions contained in The Cengage Learning Subscription and License Agreement and/or the Gale Power Search Terms and Conditions and by using the machine generated PDF functionality you agree to forgo any and all claims against Cengage Learning or its licensors for your use of the machine generated PDF functionality and any output derived therefrom.

Findings from Taipei Tzu Chi Hospital Advance Knowledge in Breast Cancer (Breast Cancer with Increased Drug Resistance, Invasion Ability, and Cancer Stem Cell Properties through Metabolism Reprogramming). Date: Dec. 1, 2022 From: Women's Health Weekly Publisher: NewsRX LLC Document Type: Article Length: 537 words

Full Text:  2022 DEC 1 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on breast cancer is now available. According to news reporting originating from the Taipei Tzu Chi Hospital by NewsRx correspondents, research stated, "Breast cancer is a heterogeneous disease, and the survival rate of patients with breast cancer strongly depends on their stage and clinicopathological features. Chemoradiation therapy is commonly employed to improve the survivability of patients with advanced breast cancer."

Funders for this research include Ministry of Science Technology; Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation.

The news editors obtained a quote from the research from Taipei Tzu Chi Hospital: "However, the treatment process is often accompanied by the development of drug resistance, which eventually leads to treatment failure. Metabolism reprogramming has been recognized as a mechanism of breast cancer resistance. In this study, we established a doxorubicin-resistant MCF-7 (MCF-7- D500) cell line through a series of long-term doxorubicin in vitro treatments. Our data revealed that MCF-7-D500 cells exhibited increased multiple-drug resistance, cancer stemness, and invasiveness compared with parental cells. We analyzed the metabolic profiles of MCF-7 and MCF-7-D500 cells through liquid chromatography-mass spectrometry. We observed significant changes in 25 metabolites, of which, 21 exhibited increased levels (>1.5-fold change and * * p* * < 0.05) and 4 exhibited decreased levels (<0.75- fold change and * * p* * < 0.05) in MCF-7 cells with doxorubicin resistance. These results suggest the involvement of metabolism reprogramming in the development of drug resistance in breast cancer, especially the activation of glycolysis, the tricarboxylic acid (TCA) cycle, and the hexamine biosynthesis pathway (HBP)."

According to the news editors, the research concluded: "Furthermore, most of the enzymes involved in glycolysis, the HBP, and the TCA cycle were upregulated in MCF-7-D500 cells and contributed to the poor prognosis of patients with breast cancer. Our findings provide new insights into the regulation of drug resistance in breast cancer, and these drug resistance-related metabolic pathways can serve as targets for the treatment of chemoresistance in breast cancer."

For more information on this research see: Breast Cancer with Increased Drug Resistance, Invasion Ability, and Cancer Stem Cell Properties through Metabolism Reprogramming. International Journal of Molecular Sciences, 2022,23(12875):12875. (International Journal of Molecular Sciences - http://www.mdpi.com/journal/ijms). The publisher for International Journal of Molecular Sciences is MDPI AG.

A free version of this journal article is available at https://doi.org/10.3390/ijms232112875.

Our news journalists report that additional information may be obtained by contacting Kian-Hwee Chong, Department of Surgery, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan. Additional authors for this research include Yao-Jen Chang, Wei-Hsin Hsu, Ya-Ting Tu, Yi-Ru Chen, Ming-Cheng Lee, Kuo-Wang Tsai.

Keywords for this news article include: Taipei Tzu Chi Hospital, Antibiotics, Antineoplastics, Pharmaceuticals, Oncology, Breast Cancer, Women's Health, Drug Resistance, Stem Cell Research, Doxorubicin Therapy, Drugs and Therapies, Health and Medicine.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2022, NewsRx LLC

The citation for this news report is: NewsRx. Findings from Taipei Tzu Chi Hospital Advance Knowledge in Breast Cancer (Breast Cancer with Increased Drug Resistance, Invasion Ability, and Cancer Stem Cell Properties through Metabolism Reprogramming). Women's Health Weekly. December 1, 2022; p 211.

Copyright: COPYRIGHT 2022 NewsRX LLC http://www.newsrx.com/newsletters/Womens-Health-Weekly.html Source Citation (MLA 9th Edition)    "Findings from Taipei Tzu Chi Hospital Advance Knowledge in Breast Cancer (Breast Cancer with Increased Drug Resistance,

Invasion Ability, and Cancer Stem Cell Properties through Metabolism Reprogramming)." Women's Health Weekly, 1 Dec. 2022, p. 211. Gale OneFile: Business, link.gale.com/apps/doc/A728037888/GPS?u=lirn50909&sid=bookmark-GPS&xid=ee0d9497. Accessed 7 Feb. 2023.

Gale Document Number: GALE|A728037888